BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

Novavax Inc. (NASDAQ:NVAX), which expects Phase I data for its COVID-19 vaccine in July, hired Filip Dubovsky as SVP and CMO. He succeeds CMO Louis Fries, who has retired. Dubovsky was head of clinical engagement...
BioCentury | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

...general partner. Agarwala was previously a venture partner on the life sciences team at GV. Cambrex Corp....
...small molecule CDMO company promoted EVP Shawn Cavanagh to president while retaining his COO title. Cambrex...
...U.S. exploratory development and strategic planning; he has written several books since then. BioCentury Staff IFM Therapeutics LLC Cambrex Corp. Alzheon...
BioCentury | Aug 9, 2019
Company News

Aug. 8 Company Quick Takes: Amarin tumbles on Vascepa update; plus Alexandria, Cambrex, Kala and miRagen

...Deals" ). PE firm buying CRO Cambrex European private equity firm Permira Funds will acquire Cambrex Corp....
...$2.4 billion, which includes the CRO's net debt. The price is a 47% premium to Cambrex's...
...Loteprednol etabonate mucosal penetrating particle (KPI-121) MRG-110 (S95010) MRG-201 (MiR-29) Vascepa (amr101, icosapent ethyl, miraxion, AMR-101, LAX-101) Amarin Corp. plc Cambrex Corp. Kala...
BioCentury | May 5, 2014
Company News

Cambrex board of directors update

Cambrex Corp. (NYSE:CBM), East Rutherford, N.J. Business: Supply/Service, Agbio/Environmental Transitioned: Shlomo Yanai to non-executive chairman from non-executive vice chairman, formerly president and CEO of Teva Pharmaceutical Industries Ltd. ; he replaces John Miller, who retired...
BioCentury | Dec 3, 2012
Company News

Cambrex board of directors update

Cambrex Corp. (NYSE:CBM), East Rutherford, N.J. Business: Supply/Service, Agbio/Environmental Appointed: Shlomo Yanai as non-executive vice chairman, formerly president and CEO of Teva Pharmaceutical Industries Ltd. WIR Staff...
BioCentury | Jul 11, 2011
Company News

Cambrex, Zeria deal

...Cambrex granted Zeria's Tillotts Pharma AG subsidiary exclusive, worldwide rights to use Cambrex's mesalamine-based technology to...
...milestones and royalties. Cambrex has exclusive rights to the technology from PLx Pharma (Houston, Texas). Cambrex Corp....
BioCentury | Feb 21, 2011
Company News

Cambrex management update

Cambrex Corp. (NYSE:CBM), East Rutherford, N.J. Business: Supply/Service, Agbio/Environmental Hired: Shawn Cavanagh as EVP and COO, formerly president of Lonza Bioscience at Lonza Group AG WIR Staff...
BioCentury | Nov 15, 2010
Company News

Cambrex, Zenara Pharma deal

...the remaining 49% of the company, which will be renamed Cambrex Zenara, in early 2016. Cambrex...
...said the acquisition will allow it to expand into India. Further details were not disclosed. Cambrex Corp....
BioCentury | Jun 28, 2010
Company News

KemPharm management update

...Johnson, a director, as chief commercial officer, formerly director of R&D and controlled substances at Cambrex Corp. WIR...
BioCentury | May 19, 2008
Company News

Cambrex board of directors update

Cambrex Corp. (NYSE:CBM), East Rutherford, N.J. Business: Supply/Service, Agbio/Environmental Appointed: Lead director John Miller as chairman WIR Staff...
Items per page:
1 - 10 of 76
BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

Novavax Inc. (NASDAQ:NVAX), which expects Phase I data for its COVID-19 vaccine in July, hired Filip Dubovsky as SVP and CMO. He succeeds CMO Louis Fries, who has retired. Dubovsky was head of clinical engagement...
BioCentury | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

...general partner. Agarwala was previously a venture partner on the life sciences team at GV. Cambrex Corp....
...small molecule CDMO company promoted EVP Shawn Cavanagh to president while retaining his COO title. Cambrex...
...U.S. exploratory development and strategic planning; he has written several books since then. BioCentury Staff IFM Therapeutics LLC Cambrex Corp. Alzheon...
BioCentury | Aug 9, 2019
Company News

Aug. 8 Company Quick Takes: Amarin tumbles on Vascepa update; plus Alexandria, Cambrex, Kala and miRagen

...Deals" ). PE firm buying CRO Cambrex European private equity firm Permira Funds will acquire Cambrex Corp....
...$2.4 billion, which includes the CRO's net debt. The price is a 47% premium to Cambrex's...
...Loteprednol etabonate mucosal penetrating particle (KPI-121) MRG-110 (S95010) MRG-201 (MiR-29) Vascepa (amr101, icosapent ethyl, miraxion, AMR-101, LAX-101) Amarin Corp. plc Cambrex Corp. Kala...
BioCentury | May 5, 2014
Company News

Cambrex board of directors update

Cambrex Corp. (NYSE:CBM), East Rutherford, N.J. Business: Supply/Service, Agbio/Environmental Transitioned: Shlomo Yanai to non-executive chairman from non-executive vice chairman, formerly president and CEO of Teva Pharmaceutical Industries Ltd. ; he replaces John Miller, who retired...
BioCentury | Dec 3, 2012
Company News

Cambrex board of directors update

Cambrex Corp. (NYSE:CBM), East Rutherford, N.J. Business: Supply/Service, Agbio/Environmental Appointed: Shlomo Yanai as non-executive vice chairman, formerly president and CEO of Teva Pharmaceutical Industries Ltd. WIR Staff...
BioCentury | Jul 11, 2011
Company News

Cambrex, Zeria deal

...Cambrex granted Zeria's Tillotts Pharma AG subsidiary exclusive, worldwide rights to use Cambrex's mesalamine-based technology to...
...milestones and royalties. Cambrex has exclusive rights to the technology from PLx Pharma (Houston, Texas). Cambrex Corp....
BioCentury | Feb 21, 2011
Company News

Cambrex management update

Cambrex Corp. (NYSE:CBM), East Rutherford, N.J. Business: Supply/Service, Agbio/Environmental Hired: Shawn Cavanagh as EVP and COO, formerly president of Lonza Bioscience at Lonza Group AG WIR Staff...
BioCentury | Nov 15, 2010
Company News

Cambrex, Zenara Pharma deal

...the remaining 49% of the company, which will be renamed Cambrex Zenara, in early 2016. Cambrex...
...said the acquisition will allow it to expand into India. Further details were not disclosed. Cambrex Corp....
BioCentury | Jun 28, 2010
Company News

KemPharm management update

...Johnson, a director, as chief commercial officer, formerly director of R&D and controlled substances at Cambrex Corp. WIR...
BioCentury | May 19, 2008
Company News

Cambrex board of directors update

Cambrex Corp. (NYSE:CBM), East Rutherford, N.J. Business: Supply/Service, Agbio/Environmental Appointed: Lead director John Miller as chairman WIR Staff...
Items per page:
1 - 10 of 76